These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 26889247)
41. Pemetrexed and bevacizumab-containing chemotherapy for pleomorphic carcinoma of the lung. Tamura T; Ohara G; Kagohashi K; Kawaguchi M; Kurishima K; Satoh H Mol Clin Oncol; 2016 Apr; 4(4):616-618. PubMed ID: 27073676 [TBL] [Abstract][Full Text] [Related]
42. Rationale and Design of a Randomized Phase 2 Trial of Gefitinib Plus Bevacizumab vs Gefitinib Alone in Patients with Epidermal Growth Factor Receptor Mutant Non-Squamous Non-Small-Cell Lung Cancer: Study Protocol. Kitagawa C; Kada A; Saito AM; Ichinose Y; Saka H Kurume Med J; 2019 May; 65(2):77-81. PubMed ID: 30429415 [TBL] [Abstract][Full Text] [Related]
43. [A Patient with Lung Adenocarcinoma, Lymphangitis Carcinomatosa, and Multiple Bone Metastases Who Achieved Long-Term Survival after Successful Treatment with Carboplatin, Paclitaxel, and Bevacizumab]. Suzuki E; Tanahashi M; Yukiue H; Yoshii N; Shitara M; Fujino T; Niwa H Gan To Kagaku Ryoho; 2016 May; 43(5):617-20. PubMed ID: 27210094 [TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis. Zhao Y; Liu J; Cai X; Pan Z; Liu J; Yin W; Chen H; Xie Z; Liang H; Wang W; Guo Z; Zhao S; Liang W; He J BMJ; 2019 Oct; 367():l5460. PubMed ID: 31591158 [TBL] [Abstract][Full Text] [Related]
45. Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung Cancer. Weiss JM; Villaruz LC; O'Brien J; Ivanova A; Lee C; Olson JG; Pollack G; Gorman R; Socinski MA; Stinchombe TE Clin Lung Cancer; 2016 Mar; 17(2):128-32. PubMed ID: 26774201 [TBL] [Abstract][Full Text] [Related]
46. Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015. Kozuki T; Nogami N; Kitajima H; Iwasawa S; Sakaida E; Takiguchi Y; Ikeda S; Yoshida M; Kato T; Miyamoto S; Sakamaki K; Shinkai T; Watanabe K BMC Cancer; 2016 May; 16():306. PubMed ID: 27177035 [TBL] [Abstract][Full Text] [Related]
47. Late-stage metastasis to the choroid from follicular thyroid carcinoma--case report. Seneviratne DR; Stavrou P; Good P Optometry; 2011 Apr; 82(4):215-7. PubMed ID: 21439488 [TBL] [Abstract][Full Text] [Related]
48. Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001. Ichihara E; Hotta K; Nogami N; Kuyama S; Kishino D; Fujii M; Kozuki T; Tabata M; Harada D; Chikamori K; Aoe K; Ueoka H; Hosokawa S; Bessho A; Hisamoto-Sato A; Kubo T; Oze I; Takigawa N; Tanimoto M; Kiura K J Thorac Oncol; 2015 Mar; 10(3):486-91. PubMed ID: 25695221 [TBL] [Abstract][Full Text] [Related]
49. Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116. Casey EM; Harb W; Bradford D; Bufill J; Nattam S; Patel J; Fisher W; Latz JE; Li X; Wu J; Hanna N J Thorac Oncol; 2010 Nov; 5(11):1815-20. PubMed ID: 20881647 [TBL] [Abstract][Full Text] [Related]
50. Complete remission of gestational choriocarcinoma with choroidal metastasis treated with systemic chemotherapy alone: case report and review of literature. Ino K; Mitsui T; Nomura S; Kikkawa F; Mizutani S Gynecol Oncol; 2001 Dec; 83(3):601-4. PubMed ID: 11733980 [TBL] [Abstract][Full Text] [Related]
51. Successful pemetrexed-containing chemotherapy for epidermal growth factor receptor mutation-positive adenosquamous cell carcinoma of the lung: A case report. Watanabe H; Tamura T; Kagohashi K; Kawaguchi M; Kurishima K; Satoh H Mol Clin Oncol; 2016 Apr; 4(4):628-630. PubMed ID: 27073680 [TBL] [Abstract][Full Text] [Related]
52. Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations. Uchibori K; Satouchi M; Sueoka-Aragane N; Urata Y; Sato A; Imamura F; Inoue T; Tachihara M; Kobayashi K; Katakami N; Kokan C; Hirashima T; Iwanaga K; Mori M; Aoe K; Morita S; Negoro S Lung Cancer; 2018 Oct; 124():65-70. PubMed ID: 30268482 [TBL] [Abstract][Full Text] [Related]
53. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514 [TBL] [Abstract][Full Text] [Related]